Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Larry Alphs

Showing results (1-10 of 120) with videos related to

Pageof 12
Sort By:
Schizophrenia Bulletin|February 14, 2006
An industry perspective on the NIMH consensus statement on negative symptomsLarry Alphs
Journal of Clinical Psychopharmacology|April 7, 2025
Incorporating Real-World Treatment Data Into Clozapine's Product LabelLarry Alphs
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|January 26, 2013
Limited utility of number needed to treat and the polarity index for bipolar disorder to characterize treatment responseLarry Alphs, Joris Berwaerts, Ibrahim Turkoz
Schizophrenia Bulletin|June 15, 2007
Wayne Fenton's impact on industryAlan Breier, Larry Alphs, Brendon Binneman
Psychopharmacology Bulletin|May 22, 2007
Asenapine in the treatment of negative symptoms of schizophrenia: clinical trial design and rationaleLarry Alphs, John Panagides, Scott Lancaster
Journal of Managed Care & Specialty Pharmacy|July 31, 2018
Projecting the Potential Effect of Using Paliperidone Palmitate Once-Monthly and Once-Every-3-Months Long-Acting Injections Among Medicaid Beneficiaries with SchizophreniaAnirban Basu, Carmela Benson, Larry Alphs
Pharmaceutical Statistics|September 18, 2018
Application of Bayesian analyses to doubly randomized delayed start, matched control designs to demonstrate disease modificationIbrahim Turkoz, Marc Sobel, Larry Alphs
Schizophrenia Research|May 21, 2014
How study designs influence comparative effectiveness outcomes: the case of oral versus long-acting injectable antipsychotic treatments for schizophreniaLarry Alphs, Nina Schooler, John Lauriello
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|April 30, 2013
Response to Drs. Citrome and KetterLarry Alphs, Ibrahim Turkoz, Joris Berwaerts
Early Intervention in Psychiatry|January 28, 2016
Re: Review article titled 'Clinical benefits and impact of early use of long-acting injectable antipsychotics for schizophrenia' (Stevens GL et al. Early Interv Psychiatry 2015 Sep 25. doi: 10.1111/eip.12278)Larry Alphs, Cynthia Bossie, Jennifer Kern Sliwa
Pageof 12

Showing results (1-10 of 120) with videos related to

Sort By:
Pageof 12
Schizophrenia Bulletin|February 14, 2006
An industry perspective on the NIMH consensus statement on negative symptomsLarry Alphs
Journal of Clinical Psychopharmacology|April 7, 2025
Incorporating Real-World Treatment Data Into Clozapine's Product LabelLarry Alphs
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|January 26, 2013
Limited utility of number needed to treat and the polarity index for bipolar disorder to characterize treatment responseLarry Alphs, Joris Berwaerts, Ibrahim Turkoz
Schizophrenia Bulletin|June 15, 2007
Wayne Fenton's impact on industryAlan Breier, Larry Alphs, Brendon Binneman
Psychopharmacology Bulletin|May 22, 2007
Asenapine in the treatment of negative symptoms of schizophrenia: clinical trial design and rationaleLarry Alphs, John Panagides, Scott Lancaster
Journal of Managed Care & Specialty Pharmacy|July 31, 2018
Projecting the Potential Effect of Using Paliperidone Palmitate Once-Monthly and Once-Every-3-Months Long-Acting Injections Among Medicaid Beneficiaries with SchizophreniaAnirban Basu, Carmela Benson, Larry Alphs
Pharmaceutical Statistics|September 18, 2018
Application of Bayesian analyses to doubly randomized delayed start, matched control designs to demonstrate disease modificationIbrahim Turkoz, Marc Sobel, Larry Alphs
Schizophrenia Research|May 21, 2014
How study designs influence comparative effectiveness outcomes: the case of oral versus long-acting injectable antipsychotic treatments for schizophreniaLarry Alphs, Nina Schooler, John Lauriello
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|April 30, 2013
Response to Drs. Citrome and KetterLarry Alphs, Ibrahim Turkoz, Joris Berwaerts
Early Intervention in Psychiatry|January 28, 2016
Re: Review article titled 'Clinical benefits and impact of early use of long-acting injectable antipsychotics for schizophrenia' (Stevens GL et al. Early Interv Psychiatry 2015 Sep 25. doi: 10.1111/eip.12278)Larry Alphs, Cynthia Bossie, Jennifer Kern Sliwa
Pageof 12